Join to view full profile
1515 Holcombe BlvdHouston, TX 77030
Phone+1 713-792-6161
Dr. Ajani is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 1980 - 1982
Tulane UniversityResidency, Internal Medicine, 1977 - 1980
UPMC Medical Education/Altoona HospitalResidency, Family Medicine, 1975 - 1977
UPMC Medical Education/Altoona HospitalInternship, Transitional Year, 1974 - 1975
Indira Gandhi Medical CollegeClass of 1971
Certifications & Licensure
FL State Medical License 2021 - Present
AZ State Medical License 2024 - 2028
GA State Medical License 2024 - 2027
MS State Medical License 2024 - 2027
OK State Medical License 2020 - 2027
TN State Medical License 2024 - 2027
TX State Medical License 1980 - 2027
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology- Join now to see all
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification ClinicStation, UT MD Anderson Cancer Center, 2013, 2015
Publications & Presentations
PubMed
- 1 citationsEvaluating the pharmacokinetics of zolbetuximab in gastric adenocarcinoma.Jane E Rogers, Michael Leung, Jaffer A Ajani
Expert Opinion on Drug Metabolism & Toxicology. 2025-05-01 - 10 citationsPhase 2 study of futibatinib in patients with gastric or gastroesophageal junction cancer harboring FGFR2 amplifications.Taroh Satoh, Philippe Barthélémy, Lucia Nogova, Kazunori Honda, Hidekazu Hirano
European Journal of Cancer. 2025-03-11 - 1 citationsContemporary management of advanced gastric and gastroesophageal adenocarcinomas.Jane E Rogers, Jaffer A Ajani
Expert Review of Anticancer Therapy. 2025-02-08
Journal Articles
- Surgeon Assessment of Gastric Cancer Lymph Node Specimens with a Video of TechniquePaul F Mansfield, Wayne L Hofstetter, Keith F Fournier, Brian D Badgwell, Journal of gastrointestinal surgery
- Preoperative Therapy for Gastric Adenocarcinoma Is Protective for Poor OncologicDiego Vicente, Paul Mansfield, Brian D Badgwell, Keith Fournier, Jaffer Ajani, Annals of Surgical Oncology
Lectures
- Phase I study of DFP-11207, a novel oral 5-FU with enhanced PK and improved2019 ASCO Annual Meeting - 6/1/2019
- 'Medical Oncology and Hematology 2012: Clinical and Scientific Approaches thatThe University of Texas, M. D. Anderson Cancer Center, Houston, Texas - 10/18/2012
- The Ninth Annual Meeting of the International Society of Gastrointestinal OncologyThe Johns Hopkins University School of Medicine, Arlington, Virginia - 9/13/2012
Press Mentions
FLOT Reduces CLDN18.2 in Gastric Cancer, Raising Questions About TargetingSeptember 16th, 2025
New Insights into Biology, Origin of Deadly Stomach and Esophageal CancersOctober 27th, 2022
Immunotherapy Is Now the First Choice for Esophageal CancerMay 31st, 2022
Grant Support
- Common Stem Cell of Origin for Junctional and Gastric AdenocarcinomaWAKE FOREST UNIVERSITY HEALTH SCIENCES2022–2027
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:













